Clinical trial · Observational
Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer patients have a well-known and higher risk of vaccine-preventable disease (VPD) than the general population. VPD can cause serious complications due to compromised immune system, malnutrition and the same oncology treatments and represent a severe financial burden with a delay in treating the underlying cancer The main purpose of this survey is to analyse the perception of cancer patients on the topic vaccines and vaccine-preventable diseases, the acceptability of vaccines and the evaluation of the determining factors associated with the choice of the patient to be vaccinated or not. This information will be used to improve the management of these issues.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Patients | — | UNRESOLVED | — |
| Vaccine-Preventable Diseases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- assess the proportion of vaccinated subjects in our cohort of cancer patients undergoing active cancer treatment
- timeFrame
- 3 months
- description
- The primary endpoint will be to assess the proportion of vaccinated subjects in the investigators cohort of cancer patients undergoing active cancer treatment (number of patients who received at least one vaccine/ total number of patients)
Secondary outcomes (5)
- measure
- assess the proportion of vaccinated subjects with the anti flu vaccine in the investigators cohort of cancer patients undergoing active cancer treatment
- timeFrame
- 3 months
- measure
- assess the proportion of vaccinated subjects with anti SARS-CoV-2 vaccine in the investigators cohort of cancer patients undergoing active cancer treatment
- timeFrame
- 3 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. \>18 years of age; 2. Oncology patient defined as a patient with solid tumors undergoing active systemic treatment or follow-up; 3. Written informed consent Exclusion Criteria: 1. Patients with hematological tumors 2. Patients who are unable to understand informed consent document
References
Publications (0)
Data not yet available